title: [Medication of the month. Tazarotene 0.05%-0.1% (Zorac)].
abstract: Since April 28th, a new topical retinoid is available in Belgium: tazarotene (Zorac) gel (Pierre Fabre). It exists at two concentrations: 0.05% or 0.1%. It is the first receptor-selective topical retinoid. It is indicated in the treatment of plaque-type psoriasis. In the USA, tazarotene is also licensed for use in the treatment of acne and several studies show its efficacy for the treatment of other skin diseases like photodamage and ichthyoses.
authors.affiliation: Centre Hospitalier Universitaire de Liège, Service de Dermatologie.
authors.forename: A
authors.initials: A
authors.lastname: Henno
authors.forename: M T
authors.initials: MT
authors.lastname: Hua
authors.forename: M
authors.initials: M
authors.lastname: de la Brassinne
mesh_terms: D000287:Administration, Topical; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007057:Ichthyosis / Q000188:drug therapy; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D013471:Sunburn / Q000188:drug therapy; D012176:Retinoids
chemical_list: D003879:Dermatologic Agents; D009539:Nicotinic Acids; C086827:tazarotene; D012176:Retinoids